See more : Chilco River Holdings, Inc. (CRVH) Income Statement Analysis – Financial Results
Complete financial analysis of Polus BioPharm Inc. (007630.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Polus BioPharm Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Caterpillar Inc. (CATR.PA) Income Statement Analysis – Financial Results
- Fujian Boss Software Corp. (300525.SZ) Income Statement Analysis – Financial Results
- Euromoney Institutional Investor PLC (EMYIF) Income Statement Analysis – Financial Results
- Data443 Risk Mitigation, Inc. (ATDS) Income Statement Analysis – Financial Results
- Jiangsu Expressway Company Limited (0177.HK) Income Statement Analysis – Financial Results
Polus BioPharm Inc. (007630.KS)
About Polus BioPharm Inc.
Polus BioPharm Inc. operates as a biopharmaceutical company in South Korea. Its products in pipeline includes PDP808, an insulin glargine biosimilar for treating diabetes; PDP805, a somatropin biosimilar used for treating growth hormone deficiency; PDP807, a ranibizumab biosimilar for the treatment of macular degeneration; and PDP815, an insulin lispro biosimilar used for treating diabetes. The company was formerly known as Amnis Co., Ltd. and changed its name to Polus BioPharm Inc. in December 2017. Polus BioPharm Inc. was founded in 1972 and is based in Seoul, South Korea.
| Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.52B | 9.49B | 10.16B | 29.62B | 29.86B | 39.16B | 58.74B | 54.75B | 53.71B | 37.09B | 47.59B | 40.08B | 55.27B | 26.95B |
| Cost of Revenue | 5.88B | 8.65B | 9.23B | 28.45B | 28.11B | 33.32B | 43.74B | 44.04B | 38.29B | 27.12B | 34.86B | 28.22B | 38.22B | 17.76B |
| Gross Profit | 636.32M | 838.29M | 929.06M | 1.17B | 1.75B | 5.84B | 15.00B | 10.71B | 15.42B | 9.97B | 12.72B | 11.86B | 17.05B | 9.19B |
| Gross Profit Ratio | 9.77% | 8.84% | 9.14% | 3.96% | 5.86% | 14.92% | 25.54% | 19.56% | 28.71% | 26.89% | 26.73% | 29.58% | 30.85% | 34.10% |
| Research & Development | 0.00 | 0.00 | 317.11M | 636.49M | 515.76M | 1.74B | 1.48B | 1.15B | 1.56B | 2.68B | 2.33B | 2.25B | 2.07B | 1.51B |
| General & Administrative | 100.39M | 365.62M | 885.40M | 308.96M | 482.69M | 880.91M | 856.75M | 992.36M | 897.86M | 999.39M | 991.44M | 1.23B | 892.91M | 694.80M |
| Selling & Marketing | 1.23B | 1.03B | 2.63B | 2.44B | 2.40B | 852.00M | 806.66M | 843.80M | 1.10B | 935.99M | 1.38B | 1.93B | 1.98B | 797.12M |
| SG&A | 1.33B | 1.39B | 3.51B | 2.75B | 2.88B | 1.73B | 1.66B | 1.84B | 1.99B | 1.94B | 2.37B | 3.16B | 2.87B | 1.49B |
| Other Expenses | 1.64B | 3.57B | 6.47B | 2.85B | 3.92B | 10.31B | 8.56B | 14.10B | 9.45B | 8.74B | 7.68B | 6.80B | 6.76B | 5.57B |
| Operating Expenses | 2.97B | 4.96B | 10.30B | 6.24B | 7.32B | 13.78B | 11.69B | 17.09B | 13.00B | 13.36B | 12.38B | 12.21B | 11.69B | 8.57B |
| Cost & Expenses | 8.85B | 13.61B | 19.54B | 34.69B | 35.43B | 47.10B | 55.43B | 61.13B | 51.29B | 40.47B | 47.25B | 40.44B | 49.92B | 26.33B |
| Interest Income | 23.67M | 33.72M | 110.93M | 48.45M | 207.10M | 613.51M | 633.44M | 524.79M | 368.32M | 506.58M | 445.63M | 1.23B | 964.73M | 395.43M |
| Interest Expense | 1.63B | 6.23B | 21.55B | 1.02B | 1.26B | 1.37B | 1.48B | 1.76B | 2.44B | 2.03B | 1.97B | 2.29B | 2.47B | 957.66M |
| Depreciation & Amortization | 469.88M | 959.11M | 635.92M | 356.41M | 944.09M | 1.77B | 1.63B | 2.48B | 2.16B | 1.90B | 1.47B | 1.43B | 1.36B | 1.20B |
| EBITDA | -2.24B | -6.07B | -2.16B | -1.58B | -12.68B | -5.65B | 4.26B | -10.13B | 5.04B | -2.09B | -9.38B | 1.90B | 6.84B | 2.30B |
| EBITDA Ratio | -34.44% | -63.96% | -21.29% | -5.35% | -42.48% | -14.43% | 7.25% | -18.50% | 9.38% | -5.64% | -19.70% | 4.74% | 12.38% | 8.53% |
| Operating Income | -2.33B | -4.12B | -9.37B | -5.06B | -5.57B | -7.94B | 3.31B | -6.38B | 2.42B | -3.39B | 338.56M | -354.04M | 5.36B | 620.45M |
| Operating Income Ratio | -35.83% | -43.44% | -92.22% | -17.09% | -18.65% | -20.28% | 5.63% | -11.66% | 4.50% | -9.13% | 0.71% | -0.88% | 9.69% | 2.30% |
| Total Other Income/Expenses | -2.01B | -9.14B | -14.55B | 2.09B | -4.65B | -848.84M | -2.17B | -7.99B | -1.98B | -2.64B | -13.15B | -1.46B | -2.34B | -485.55M |
| Income Before Tax | -4.34B | -13.26B | -23.92B | -2.98B | -10.22B | -8.79B | 1.14B | -14.37B | 438.76M | -6.02B | -12.81B | -1.82B | 3.01B | 134.90M |
| Income Before Tax Ratio | -66.65% | -139.79% | -235.36% | -10.05% | -34.24% | -22.44% | 1.94% | -26.25% | 0.82% | -16.24% | -26.93% | -4.54% | 5.45% | 0.50% |
| Income Tax Expense | -379.83M | -2.91B | 7.01B | 4.16M | 2.56B | -3.93M | -2.80M | -898.42M | -148.63M | 580.26M | -48.34M | -595.30M | -626.43M | -235.46M |
| Net Income | -4.34B | -13.26B | -24.35B | -2.97B | -17.45B | -8.78B | 1.14B | -13.47B | 587.38M | -6.60B | -12.76B | -1.22B | 3.64B | 370.35M |
| Net Income Ratio | -66.65% | -139.79% | -239.63% | -10.02% | -58.43% | -22.43% | 1.95% | -24.61% | 1.09% | -17.80% | -26.82% | -3.05% | 6.58% | 1.37% |
| EPS | -108.34 | -346.57 | -779.99 | -164.85 | -1.26K | -746.42 | 97.20 | -1.14K | 49.91 | -561.06 | -1.09K | -105.00 | 310.00 | 42.50 |
| EPS Diluted | -108.34 | -346.57 | -779.99 | -164.85 | -1.26K | -746.42 | 97.20 | -1.14K | 49.91 | -561.06 | -1.09K | -105.00 | 310.00 | 42.50 |
| Weighted Avg Shares Out | 40.09M | 38.26M | 31.22M | 18.01M | 13.85M | 11.77M | 11.77M | 11.77M | 11.77M | 11.77M | 11.76M | 11.65M | 11.74M | 8.71M |
| Weighted Avg Shares Out (Dil) | 40.09M | 38.26M | 31.22M | 18.01M | 13.85M | 11.77M | 11.77M | 11.77M | 11.77M | 11.77M | 11.76M | 11.65M | 11.74M | 8.71M |
Source: https://incomestatements.info
Category: Stock Reports